指南与共识复苏、休克与脓毒症心脑血管急症

全球院外心脏骤停:国际复苏联络委员会(ILCOR)首份报告

Out-of-hospital cardiac arrest across the World: First report from the International Liaison Committee on Resuscitation (ILCOR).
PubMed 文献 · Resuscitation · 2020-04-06
一句话结论ILCOR汇总9个国家与7个地区注册研究显示,急救医疗服务(EMS)救治的院外心脏骤停(OHCA)年发病率30.0–97.1/10万,出院或30天生存率3.1%–20.4%,各国差异明显。

ILCOR成立研究与注册工作组,对自愿参加的国家和地区OHCA注册研究开展两次调查:第一次确定各注册研究收集了当前Utstein格式的哪些核心要素,第二次收集描述性汇总数据。共纳入9个国家注册和7个地区注册。EMS救治的OHCA估算年发病率为30.0–97.1/10万人;中位年龄64–79岁,所有16个注册研究中男性均超过一半。旁观者心肺复苏(CPR)实施率为19.1%–79.0%,旁观者自动体外除颤器(AED)使用率在11个注册研究中为2.0%–37.4%。EMS救治的OHCA出院或30天生存率为3.1%–20.4%,出院或30天神经功能良好结局为2.8%–18.2%;旁观者目击的可除颤OHCA出院或30天生存率为11.7%–47.4%,神经功能良好结局为9.9%–33.3%。

要点

  • EMS救治的OHCA估算年发病率为30.0–97.1/10万人,数据来自9个国家与7个地区注册研究。
  • EMS救治的OHCA出院或30天生存率为3.1%–20.4%,神经功能良好结局为2.8%–18.2%。
  • 旁观者目击的可除颤OHCA出院或30天生存率为11.7%–47.4%,神经功能良好结局为9.9%–33.3%。
  • 旁观者CPR实施率为19.1%–79.0%;11个注册研究的旁观者AED使用率为2.0%–37.4%。
  • 所有16个注册研究中男性均超过一半,中位年龄64–79岁。

适用人群与场景

  • 纳入自愿参加的国家和地区OHCA注册研究:第一次调查纳入7个国家注册和4个地区注册,第二次调查纳入9个国家注册和7个地区注册。
  • 数据覆盖EMS救治的OHCA,以及旁观者目击的可除颤OHCA亚组。

研究设计与关键结果

  • 研究类型为两次调查:第一次调查确定各注册研究收集的当前Utstein格式OHCA核心要素,第二次调查收集描述性汇总数据。
  • EMS救治的OHCA估算年发病率为30.0–97.1/10万人。
  • 中位年龄64–79岁,所有16个注册研究中男性均超过一半。
  • 旁观者CPR实施率为19.1%–79.0%;11个注册研究的旁观者AED使用率为2.0%–37.4%。
  • EMS救治的OHCA出院或30天生存率为3.1%–20.4%,出院或30天神经功能良好结局为2.8%–18.2%。
  • 旁观者目击的可除颤OHCA出院或30天生存率为11.7%–47.4%,神经功能良好结局为9.9%–33.3%。

证据类型、等级与局限

  • 证据类型:国际复苏联络委员会(ILCOR)研究与注册工作组开展的两次注册研究调查。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

指南或共识出处

  • 国际复苏联络委员会(ILCOR)研究与注册工作组报告,发表于Resuscitation。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Since development of the Utstein style recommendations for the uniform reporting of cardiac arrest, increasing numbers of national and regional out-of-hospital cardiac arrest (OHCA) registries have been established worldwide. The International Liaison Committee on Resuscitation (ILCOR) created the Research and Registries Working Group and aimed to systematically report data collected from these registries.

METHODS: We conducted two surveys of voluntarily participating national and regional registries. The first survey aimed to identify which core elements of the current Utstein style for OHCA were collected by each registry. The second survey collected descriptive summary data from each registry. We chose the data collected for the second survey based on the availability of core elements identified by the first survey.

RESULTS: Seven national and four regional registries were included in the first survey and nine national and seven regional registries in the second survey. The estimated annual incidence of emergency medical services (EMS)-treated OHCA was 30.0-97.1 individuals per 100,000 population. The combined data showed the median age varied from 64 to 79 years and more than half were male in all 16 registries. The provision of bystander cardiopulmonary resuscitation (CPR) and bystander automated external defibrillator (AED) use was 19.1-79.0% in all registries and 2.0-37.4% among 11 registries, respectively. Survival to hospital discharge or 30-day survival after EMS-treated OHCA was 3.1-20.4% across all registries. Favorable neurological outcome at hospital discharge or 30 days after EMS-treated OHCA was 2.8-18.2%. Survival to hospital discharge or 30-day survival after bystander-witnessed shockable OHCA ranged from 11.7% to 47.4% and favorable neurological outcome from 9.9% to 33.3%.

CONCLUSION: This report from ILCOR describes data on systems of care and outcomes following OHCA from nine national and seven regional registries across the world. We found variation in reported survival outcomes and other core elements of the current Utstein style recommendations for OHCA across nations and regions.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Kiguchi T, Okubo M, Nishiyama C, et al. Out-of-hospital cardiac arrest across the World: First report from the International Liaison Committee on Resuscitation (ILCOR). Resuscitation. 2020. PMID: 32272235. doi:10.1016/j.resuscitation.2020.02.044

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。